These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37773003)

  • 1. Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Ghazipura M; Macrea M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):328-337. PubMed ID: 37773003
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Barnes H; Ghazipura M; Herman D; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Jan; 21(1):122-135. PubMed ID: 37772975
    [No Abstract]   [Full Text] [Related]  

  • 3. Nintedanib Therapy Alone and Combined with Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: Systematic Reviews and Meta-analysis.
    Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Mar; 21(3):474-485. PubMed ID: 37773000
    [No Abstract]   [Full Text] [Related]  

  • 4. Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Herman D; Ghazipura M; Barnes H; Macrea M; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Jan; 21(1):136-150. PubMed ID: 37027538
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
    Macrea M; Ghazipura M; Herman D; Barnes H; Knight SL; Silver RM; Montesi SB; Raghu G; Hossain T
    Ann Am Thorac Soc; 2024 Feb; 21(2):317-327. PubMed ID: 37772987
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
    Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
    Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tocilizumab plus Nintedanib for progressive interstitial lung disease in systemic sclerosis: a one-year observational study.
    Panopoulos S; Tzilas V; Bournia VK; Tektonidou MG; Sfikakis PP
    Rheumatol Int; 2024 Oct; 44(10):1959-1966. PubMed ID: 39180531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial.
    Bernstein EJ; Denton CP; Huang S; Khanna D
    Semin Arthritis Rheum; 2024 Apr; 65():152376. PubMed ID: 38244446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Khanna D; Lin CJF; Furst DE; Goldin J; Kim G; Kuwana M; Allanore Y; Matucci-Cerinic M; Distler O; Shima Y; van Laar JM; Spotswood H; Wagner B; Siegel J; Jahreis A; Denton CP;
    Lancet Respir Med; 2020 Oct; 8(10):963-974. PubMed ID: 32866440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial.
    Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S
    Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
    Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.
    Petelytska L; Bonomi F; Cannistrà C; Fiorentini E; Peretti S; Torracchi S; Bernardini P; Coccia C; De Luca R; Economou A; Levani J; Matucci-Cerinic M; Distler O; Bruni C
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37940340
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
    Ghuman A; Khanna D; Lin CJF; Furst DE; Raghu G; Martinez FJ; Zucchetto M; Huang S; Jennings A; Nihtyanova SI; Denton CP
    Rheumatology (Oxford); 2024 Feb; 63(2):472-481. PubMed ID: 37228011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Systemic Sclerosis-associated Interstitial Lung Disease Burn Out? Specific Phenotypes of Disease Progression.
    Guler SA; Winstone TA; Murphy D; Hague C; Soon J; Sulaiman N; Li KH; Dunne J; Wilcox PG; Ryerson CJ
    Ann Am Thorac Soc; 2018 Dec; 15(12):1427-1433. PubMed ID: 30188737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
    Roofeh D; Lin CJF; Goldin J; Kim GH; Furst DE; Denton CP; Huang S; Khanna D;
    Arthritis Rheumatol; 2021 Jul; 73(7):1301-1310. PubMed ID: 33538094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.
    Kuwana M; Takehara K; Tanaka Y; Yamashita K; Katsumata K; Takata M; Shima Y
    Mod Rheumatol; 2024 Mar; 34(3):530-540. PubMed ID: 37436828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.
    Hoffmann-Vold AM; Allanore Y; Alves M; Brunborg C; Airó P; Ananieva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Kowal-Bielecka O; Riccardi A; Distler O;
    Ann Rheum Dis; 2021 Feb; 80(2):219-227. PubMed ID: 32988845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.